Basic Stats
| LEI | 5299000AON4Q9NT2JE42 |
| CIK | 1650664 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Editas Medicine, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 2, 2025 |
Exhibit 99.1 Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBR |
|
| August 12, 2025 |
Editas Medicine Announces Second Quarter 2025 Results and Business Updates Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Presented data at ASGCT, TIDES, and EHA that validate differentiated potential of Editas’ gene upregulation strategy and in vivo delivery platform technology Strong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 12, 2025 |
Restated Certificate of Incorporation of the Registrant, as amended ex31-restatedcharterasam Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF EDITAS MEDICINE, INC. (originally incorporated on September 3, 2013 under the name Gengine, Inc.) FIRST: The name of the Corporation is Editas Medicine, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, Coun |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 12, 2025 |
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 2, 2025 |
Amended and Restated 2015 Stock Incentive Plan Editas Medicine, Inc. AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN 1.Purpose The purpose of this Amended and Restated 2015 Stock Incentive Plan (the “Plan”) of Editas Medicine, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contrib |
|
| June 2, 2025 |
Certificate of Amendment of Restated Certificate of Incorporation of Editas Medicine, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF EDITAS MEDICINE, INC. (originally incorporated on September 3, 2013 under the name Gengine, Inc.) (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Editas Medicine, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corpor |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2025 |
EX-99.1 2 editasmedicineasgctinvivoh.htm EX-99.1 Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle ce |
|
| May 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2025 |
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass. |
|
| May 12, 2025 |
Editas Medicine Announces First Quarter 2025 Results and Business Updates Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Strong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☐ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the |
|
| April 4, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 5, 2025 |
Exhibit 1.2 Editas Medicine, Inc. $300,000,000 COMMON STOCK SALES AGREEMENT May 14, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, fr |
|
| March 5, 2025 |
Exhibit 19.1 EDITAS MEDICINE, INC. Insider Trading Policy 1.BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”) or employee of Editas Medicine, Inc. (together with its subsidiaries, the “Company”) from purchasing or selling Company securities on the basis of material nonpublic information concerning th |
|
| March 5, 2025 |
Separation Agreement, dated December 16, 2024 between the Registrant and Baisong Mei ex1015separationagreemen 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 VIA HAND DELIVERY & ELECTRONIC MAIL December 16, 2024 Baisong Mei, M. |
|
| March 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 1 to Form S-3 (Form Type) Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-376 |
|
| March 5, 2025 |
ex1025-purchaseandsaleag Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-end On track to establish one additional target cell type/tissue by year-end Strong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass. |
|
| March 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Editas Medicine, Inc. |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 13, 2025 |
Exhibit 99.1 Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities •Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia •Achieved in vivo editing of liver c |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 12, 2024 |
Exhibit 99.1 Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years •Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: -Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humaniz |
|
| December 10, 2024 |
Exhibit 99.1 Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 9, 2024 – Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, will present updated sa |
|
| December 10, 2024 |
AMENDED AND RESTATED BY-LAWS OF EDITAS MEDICINE, INC. Exhibit 3.1 i TABLE OF CONTENTS Page ARTICLE I - STOCKHOLDERS 1.1 Place of Meetings .....................................................................................................1 1.2 Annual Meeting .......................................................................................................1 1.3 Special Meetings .............. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 4, 2024 |
Editas Medicine Announces Third Quarter 2024 Results and Business Updates Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outc |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 22, 2024 |
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept, and Strategic Update Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel, to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a. |
|
| October 17, 2024 |
EDIT / Editas Medicine, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 EditasMedicineInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EDITAS MEDICINE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28106W103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| October 4, 2024 |
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities CAMBRIDGE, Mass. |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2024 |
Editas Medicine Announces Second Quarter 2024 Results and Business Updates On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass. |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2024 |
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. |
|
| June 14, 2024 |
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster presentation on Friday, June 14 at 6 p. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2024 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) information of the type that the registrant customarily and actually treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This FIRST AMENDMENT TO THE SECOND AMENDED AND RES |
|
| May 8, 2024 |
Editas Medicine Announces First Quarter 2024 Results and Business Updates Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines Strong financial position with operational runway into 2026 CAMBRIDGE, Mass. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 16, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a |
|
| February 28, 2024 |
Form of Restricted Stock Unit Award Agreement under the 2015 Stock Incentive Plan Exhibit 10.10 EDITAS MEDICINE, INC. RESTRICTED STOCK UNIT AGREEMENT Editas Medicine, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2015 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of Restricted Stock Units (“RSUs”) granted: Number, if any, o |
|
| February 28, 2024 |
Exhibit 1.2 Editas Medicine, Inc. $300,000,000 COMMON STOCK SALES AGREEMENT May 14, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2024 |
Dodd-Frank Compensation Recovery Policy Exhibit 97 EDITAS MEDICINE, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Editas Medicine, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Editas Medicine, Inc. |
|
| February 28, 2024 |
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY trial Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9 Strong financial position with operational runway expected into 2026 CAMBRIDGE, Mass. |
|
| February 28, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Editas Medicine, Inc. (“we” or “us”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.0001 per share. Description of Capital Stock The following description |
|
| February 28, 2024 |
Form of Inducement Stock Option Agreement for the Registrant’s executive officers Exhibit 10.19 Editas Medicine, Inc. Inducement Stock Option Agreement 1. Grant of Option. This agreement evidences the grant by Editas Medicine, Inc., a Delaware corporation (the “Company”), on [] (the “Grant Date”) to [] (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein, a total of [] shares (the “Shares”) of common stock, $0.0001 par value per share |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Editas Medicine, Inc. |
|
| February 28, 2024 |
Form of Restricted Stock Agreement under 2015 Stock Incentive Plan Exhibit 10.9 EDITAS MEDICINE, INC. Restricted Stock Agreement 2015 Stock Incentive Plan This Restricted Stock Agreement (this “Agreement”) is made as of the Grant Date set forth below between Editas Medicine, Inc., a Delaware corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): Grant Date: Number of shares of the restricted common s |
|
| February 28, 2024 |
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| February 28, 2024 |
Form of Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan Exhibit 10.8 EDITAS MEDICINE, INC. NONSTATUTORY STOCK OPTION AGREEMENT Editas Medicine, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2015 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shar |
|
| February 28, 2024 |
Summary of Director Compensation Program Exhibit 10.27 EDITAS MEDICINE DIRECTOR COMPENSATION Under this non-employee director compensation program, Editas Medicine (the “Company”) pays its non-employee directors retainers in cash. Each non-employee director receives a cash retainer for service on the Board and for service on each committee of which the director is a member. The chairmen of the Board and of each committee receives higher |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Exhibit 4.5 EDITAS MEDICINE, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Form of Incentive Stock Option Agreement under 2015 Stock Incentive Plan Exhibit 10.7 EDITAS MEDICINE, INC. INCENTIVE STOCK OPTION AGREEMENT Editas Medicine, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2015 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shares” |
|
| February 28, 2024 |
Exhibit 4.4 EDITAS MEDICINE, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli |
|
| February 28, 2024 |
Form of Inducement Restricted Stock Unit Award Agreement for the Registrant’s executive officers Exhibit 10.20 EDITAS MEDICINE, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT Editas Medicine, Inc. (the “Company”) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): [] Grant Date: [] Number of Restricted Stock Units (“RSUs”) granted: [] Number, if any, of RSUs that vest immed |
|
| February 28, 2024 |
Omnibus Amendment, dated as of February 5, 2024, by and among the Registrant, Broad and Harvard Exhibit 10.36 OMNIBUS AMENDMENT This Omnibus Amendment (the “Amendment”) is entered into as of February 5, 2024 (the “Amendment Effective Date”), by and between on the one hand, President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Smith Campus Center, Suit |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-376 |
|
| February 28, 2024 |
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| February 14, 2024 |
EDIT / Editas Medicine, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
EDIT / Editas Medicine, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0817-editasmedicineinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Editas Medicine Inc Title of Class of Securities: Common Stock CUSIP Number: 28106W103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designa |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 13, 2023 |
ex991-pressreleaseddated Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 11, 2023 |
ex991-pressreleasedatedd Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40% All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301 infusion EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EDIT-301 is now known as renizgamglogene autogedtemcel (reni-cel) Company-sponsored webinar on the RUBY and EdiTHAL data today at 1:00 p. |
|
| November 22, 2023 |
Amended and Restated Severance Benefits Plan Exhibit 10.1 Amended and Restated Severance Benefits Plan 1.Establishment of Plan. Editas Medicine, Inc., a Delaware corporation (the “Company”), hereby establishes an unfunded severance benefits plan (the “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees who experience a Covered Termination occurring afte |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2023 |
Exhibit 99.1 Editas Medicine Announces Third Quarter 2023 Results and Business Updates Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar Granted Vor Bio a non-exclusive license for Cas9 patents for ex vivo HSC therapies for the treatment and prev |
|
| November 3, 2023 |
Separation Agreement, dated October 6, 2023 between the Registrant and Bruce Eaton separationagreement 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 VIA HAND DELIVERY & ELECTRONIC MAIL October 3, 2023 (as revised at your request on October 4, 2023) Bruce Eaton, Ph. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2023 |
EDIT / Editas Medicine Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 2, 2023 |
Separation Agreement, dated May 16, 2023, between the Registrant and Michelle Robertson Exhibit 10.2 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 VIA HAND DELIVERY May 11, 2023 (as revised at your request on May 15, 2023) Michelle Robertson Dear Michelle, As we discussed, your positions of Chief Financial Officer and Treasurer of Editas Medicine, Inc. (the “Company”) will end effective May 16, 2023 and, subject to your execution and compliance with the terms of |
|
| August 2, 2023 |
Employment Offer Letter, dated May 12, 2023, between the Registrant and Erick Lucera Exhibit 10.1 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 May 12, 2023 Erick Lucera Re: Offer of Employment Dear Erick, On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Offer Letter”) is to set forth the terms of your employment with the Company, should you accept our offer. I am please |
|
| August 2, 2023 |
Employment Offer Letter, dated July 3, 2023, between the Registrant and Linda C. Burkly Exhibit 10.3 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 July 2, 2023 Linda Burkly, Ph.D. Re: Offer of Employment Dear Linda, On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Offer Letter”) is to set forth the terms of your employment with the Company, should you accept our offer. I am |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 2, 2023 |
Exhibit 99.1 Editas Medicine Announces Second Quarter 2023 Results and Business Updates On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to provide a clinical update by year-end Strengthened Executive Team with Appointments of Erick Lucera as Chief Fin |
|
| June 15, 2023 |
12,500,000 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-253715 PROSPECTUS SUPPLEMENT (To prospectus dated March 1, 2021) 12,500,000 Shares Common Stock Editas Medicine, Inc. is offering 12,500,000 shares of its common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “EDIT.” The last reported sale price of our common stock on The Nasdaq Global |
|
| June 15, 2023 |
Exhibit 1.1 12,500,000 Shares EDITAS MEDICINE, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT June 14, 2023 June 14, 2023 J.P. Morgan Securities LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives for the several Underwriters named in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Le |
|
| June 15, 2023 |
Editas Medicine Announces Offering of Common Stock Exhibit 99.1 Editas Medicine Announces Offering of Common Stock CAMBRIDGE, Mass., June 14, 2023 – Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additio |
|
| June 15, 2023 |
Editas Medicine Announces Pricing of Offering of Common Stock Exhibit 99.2 Editas Medicine Announces Pricing of Offering of Common Stock CAMBRIDGE, Mass., June 14, 2023 – Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimate |
|
| June 15, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Editas Medicine, Inc. |
|
| June 15, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2023 |
$125,000,000 of Shares Common Stock TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 9, 2023 |
Exhibit 99.1 Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients achieved no |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 5, 2023 |
Exhibit 99.1 Editas Medicine Announces First Quarter 2023 Results and Business Updates Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY trial First patient in EDIT-301 EDITHAL trial for TDT dosed with successful |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 18, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 14, 2023 |
Amended and Restated By-laws of the Registrant Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF EDITAS MEDICINE, INC. TABLE OF CONTENTS Page ARTICLE I - STOCKHOLDERS 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Voting and Proxies 3 1.9 Action at Meeting 4 1.10 Nomination of Directors. 4 1.11 Notice of Business at Annual Meetings. 10 1.12 Conduct of |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Editas Medicine, Inc. |
|
| February 22, 2023 |
As filed with the Securities and Exchange Commission on February 22, 2023 As filed with the Securities and Exchange Commission on February 22, 2023 Registration No. |
|
| February 22, 2023 |
Subsidiaries of the Registrant EX-21.1 3 edit-20221231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries Entity State of Incorporation or Organization Editas Medicine, LLC Delaware Editas Securities Corporation Delaware |
|
| February 22, 2023 |
Exhibit 99.1 Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end On track to dose first patient in EDIT-301 EDITHAL trial for TDT |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-376 |
|
| February 22, 2023 |
Exhibit 10.32 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this "First Amendment") is made as of November 15, 2022, by and between ARE-MA REGION NO. 55, LLC, a Delaware limited liability company ("Landlord"), and EDITAS MEDICINE, INC., a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are parties to that certain Lease Agreement dated as of February 12 |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 9, 2023 |
EDIT / Editas Medicine Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0792-editasmedicineincclas.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Editas Medicine Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 28106W103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate b |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2023 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 6, 2022 |
Exhibit 99.1 Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with EDIT-301 successf |
|
| November 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 17, 2022 |
Exhibit 99.1 Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view o |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 2, 2022 |
Exhibit 99.1 Editas Medicine Announces Third Quarter 2022 Results and Business Updates Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clin |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 3, 2022 |
Exhibit 99.1 Editas Medicine Announces Second Quarter 2022 Results and Business Updates Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a enzyme FDA removed partial clinical hold for RUBY trial of EDIT-301 Con |
|
| August 3, 2022 |
Employment Offer Letter, dated April 13, 2022, between the Registrant and Gilmore O’Neill Exhibit 10.1 ? 11 Hurley Street ? Cambridge, MA 02141 ? 617-401-9000 ? 617-494-0985 ? April 13, 2022 ? By Electronic Mail ? Gilmore O?Neill, M.D. ? Dear Gilmore: ? On behalf of Editas Medicine, Inc., a Delaware corporation (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you acce |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 3, 2022 |
Employment Offer Letter, dated June 14, 2022, between the Registrant and Baisong Mei Exhibit 10.3 ? 11 Hurley Street ? Cambridge, MA 02141 ? P 617-401-9000 ? F 617-494-0985 ? June 09, 2022 ? ? ? Baisong Mei, M.D., Ph.D. ? ? ? Re: Offer of Employment ? ? Dear Baisong, On behalf of Editas Medicine, Inc. (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter (the ?Offer Letter?) is to set forth the terms of your employment with the Company, |
|
| August 3, 2022 |
Exhibit 10.2 ? ? 11 Hurley Street ? ? Cambridge, MA 02141 ? ? 617-401-9000 ? ? 617-494-0985 ? April 13, 2022 By Electronic Mail ? James C. Mullen ? Dear Jim: Reference is made to that certain Employment Offer Letter dated February 13, 2021 between Editas Medicine, Inc. (the ?Company?), and you regarding the terms of your employment with the Company (the ?Offer Letter?). This letter (the ?Amendment |
|
| August 3, 2022 |
Amendment to RSU Agreement, dated May 24, 2022, between the Registrant and James C. Mullen Exhibit 10.4 AMENDMENT TO RSU AGREEMENT Reference is made to that certain Restricted Stock Unit Agreement evidencing the restricted stock unit granted effective as of March 2, 2021 to James Mullen (the ?RSU Agreement?). The RSU Agreement is hereby amended as follows: 1.Section 7(b) of the RSU Agreement is amended by deleting the second and third sentence thereof such that Section 7(b) shall read i |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2022 |
Exhibit 99.1 Editas Medicine Announces First Quarter 2022 Results and Business Updates Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman First pediatric patient dosed in Phase 1/2 BRILLIANCE trial of EDIT-101 for LCA10; clinical data update expected in 2H 2022 On track to dose first SCD patient in 1H 2022 and first TDT patient by year-end with |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 26, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 26, 2022 |
DEFA14A 1 tm223456d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 9, 2022 |
EDIT / Editas Medicine Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0013-editasmedicineincclas.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Editas Medicine Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 28106W103 Date of Event Which Requires Filing of this Statement: February 28, 2022 Check the appropriate b |
|
| February 24, 2022 |
Amended Severance Benefits Plan Exhibit 10.28 ? ? Severance Benefits Plan ? 1.Establishment of Plan. Editas Medicine, Inc., a Delaware corporation (the ?Company?), hereby establishes an unfunded severance benefits plan (the ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees who experience a Covered Termination occurring after the Effectiv |
|
| February 24, 2022 |
EX-FILING FEES 4 tmb-20220224xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rat |
|
| February 24, 2022 |
Exhibit 99.1 ? Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates ? EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 ? EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and first TDT patient in 2022 ? EDIT-103 for RHO-adRP and EDIT-202 for solid tumors advancing towar |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 S-8 1 tmb-20220224xs8.htm S-8 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Editas Medicine, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-4097528 (State or Other Jurisdiction of Incorpor |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-376 |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
EDIT / Editas Medicine Inc / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment SC 13G/A 1 brhc10033956sc13ga.htm SC13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Editas Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) C |
|
| February 9, 2022 |
EDIT / Editas Medicine Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Editas Medicine Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 28106W103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2022 |
EDIT / Editas Medicine Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Editas Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 9, 2021 |
Exhibit 10.3 ? CONFIDENTIAL EXECUTION COPY ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SECOND AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT ? MGH Agreement No.: A221317.02 ? This Second Amendment (?Second Amendme |
|
| November 9, 2021 |
License Agreement, dated October 10, 2014, between the Registrant and Duke University Exhibit 10.4 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? LICENSE AGREEMENT ? THIS Agreement is entered into this 10th day of October, 2014 (?Effective Date?) between DUKE UNIVERSITY, a nonprofit educational and r |
|
| November 9, 2021 |
Exhibit 10.2 ? Confidential Execution Copy ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? THE GENERAL HOSPITAL CORPORATION ? EXCLUSIVE PATENT LICENSE AGREEMENT ? MGH Agreement No: A221317 MGH Case Nos: [**] ? This L |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 9, 2021 |
Exhibit 10.6 ? EXECUTION VERSION ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? License Agreement by and between PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BROAD INSTITUTE, INC. and EDITAS MEDICINE, INC. October |
|
| November 9, 2021 |
Letter Agreement, dated October 9, 2015, between the Registrant and Duke University Exhibit 10.5 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? CONFIDENTIAL ? October 9, 2015 ? Barry Myers, MD, PhD Managing Director Office of Licensing & Ventures Duke University 2812 Erwin Road, Suite 306 Durham, N |
|
| November 9, 2021 |
? Exhibit 10.7 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (this ?Agreement?), effective as of May 26, 2015 (the ?Effective Date?), is |
|
| November 9, 2021 |
Employment Offer Letter, dated September 22, 2021, between the Registrant and Bruce Eaton Exhibit 10.1 ? ? ? 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 ? ? ? September 22, 2021 ? ? Bruce Eaton ? ? Re: Employment as Chief Business Officer ? ? Dear Bruce, ? On behalf of Editas Medicine, Inc. (the ?Company?), I am pleased to inform you of your promotion to Executive Vice President and Chief Business Officer of the Company. The purpose of this letter (the ?Promotion |
|
| November 8, 2021 |
Exhibit 99.1 ? Editas Medicine Announces Third Quarter 2021 Results and Business Updates ? EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose cohorts ? EDIT-301 Phase 1/2 RUBY trial for the treatment of sickle cell disease currently enrolling study |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 29, 2021 |
Exhibit 99.1 Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose cohort provide initial support for clinical benefits Treatment in the adult high-dose cohort continues and pediatric mid-dose cohort commencing Data presen |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 5, 2021 |
Summary of Director Compensation Program Exhibit 10.3 SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective: June 15, 2021 The board of directors (the ?Board?) of Editas Medicine, Inc. (the ?Company?) has approved a non-employee director compensation program. Under this non-employee director compensation program, the Company pays its non-employee directors retainers in cash. Each non-employee director receives a cash retainer f |
|
| August 5, 2021 |
Employment Offer Letter, dated April 19, 2021, between the Registrant and Mark S. Shearman Exhibit 10.2 ? 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 ? April 19, 2021 Dr. Mark Shearman Re: Offer of Employment Dear Mark, On behalf of Editas Medicine, Inc. (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter (the ?Offer Letter?) is to set forth the terms of your employment with the Company, should you accept our offer. I am pleased to |
|
| August 4, 2021 |
Exhibit 99.1 ? Editas Medicine Announces Second Quarter 2021 Results and Business Updates ? Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10 ? EDIT-101 initial clinical data planned for September 2021 ? EDIT-301 RUBY trial for sickle cell disease screening patients; first patient on track to be dosed by year-end ? Strengthened leadership with appointment |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 8, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| May 14, 2021 |
Exhibit 1.1 Editas Medicine, Inc. $300,000,000 COMMON STOCK SALES AGREEMENT May 14, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Editas Medicine, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| May 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 14, 2021 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-253715? CALCULATION OF REGISTRATION FEE ? ? Title of Each Class of Securities Offered ? ? ? Proposed Maximum Aggregate Offering Price ? ? ? Amount of Registration Fee(1) ? Common Stock, par value $0.0001 per share ? ? ? ? $ 300,000,000 ? ? ? ? ? $ 32,730.00 ? ? ? (1) Calculated in accordance with Rule 457(o) under th |
|
| May 6, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 5, 2021 |
Exhibit 99.1 ? Editas Medicine Announces First Quarter 2021 Results and Update ? Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer ? Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end ? RUBY trial of EDIT-301 for sickle cell disease active and recruiting ? Preclinical ocular data presented at ARVO supports in vivo gene editing |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 20, 2021 |
definitive proxy statement for the 2021 Annual Meeting of Stockholders, filed on April 20, 2021; TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A? (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| March 1, 2021 |
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| March 1, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
? As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| March 1, 2021 |
Form of Subordinated Indenture Exhibit 4.5 EDITAS MEDICINE, INC. Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inap |
|
| March 1, 2021 |
Exhibit 4.4 EDITAS MEDICINE, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli |
|
| February 26, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 26, 2021 |
Letter Agreement, dated February 15, 2021, by and between the Registrant and Cynthia Collins ? ? Exhibit 10.13 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 ? VIA ELECTRONIC MAIL February 4, 2021 (revised) Cynthia Collins Dear Cindy: As we discussed, your employment with Editas Medicine, Inc. (the ?Company?) will end effective February 15, 2021 (the ?Separation Date?). As we also discussed, you will be eligible to receive the severance benefits described in paragraph |
|
| February 26, 2021 |
Summary of Director Compensation Program Exhibit 10.25 SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Effective: February 16, 2021 The board of directors (the ?Board?) of Editas Medicine, Inc. (the ?Company?) has approved a non-employee director compensation program. Under this non-employee director compensation program, the Company pays its non-employee directors retainers in cash. Each non-employee director receives a cash retai |
|
| February 26, 2021 |
Employment Offer Letter, dated February 14, 2021, between the Registrant and James C. Mullen Exhibit 10.14 ? ? ? ? ? 11 Hurley Street Cambridge, MA 02141 617-401-9000 617-494-0985 February 13, 2021 By Electronic Mail James C. Mullen Dear Jim: On behalf of Editas Medicine, Inc., a Delaware corporation (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer: |
|
| February 26, 2021 |
Exhibit 10.24 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT This Amendment (the ?SRA Amendment?) is entered into as of January 11, 2021 (the ?SRA Amendment Effective Date?), by |
|
| February 26, 2021 |
Employment Offer Letter, dated September 25, 2020, between the Registrant and Lisa A. Michaels, M.D. Exhibit 10.18 ? ? 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 September 25, 2020 Lisa A. Michaels, MD Re: Offer of Employment Dear Lisa, On behalf of Editas Medicine, Inc. (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter (the ?Offer Letter?) is to set forth the terms of your employment with the Company, should you accept our |
|
| February 26, 2021 |
Omnibus Amendment, dated as of January 11, 2021, by and between the Registrant and Broad ? Exhibit 10.32 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. OMNIBUS AMENDMENT This Omnibus Amendment (the ?Amendment?) is entered into as of January 11, 2021 (the ?Amendment Effective Date?), by and between The Broad Insti |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 25, 2021 |
Exhibit 99.1 Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board of Directors Initiated dosing of adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10 Initiated Ph |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Editas Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Editas Medicine Inc. Title of Class of Securities: Common Stock CUSIP Number: 28106W103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 8, 2021 |
Exhibit 99.1 Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective February 15, 2021 CAMBRIDGE, Mass., Feb. 8, 2021 – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mu |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Editas Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28106W103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 29, 2021 |
us28106w1036012921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) EDITAS MEDICINE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 28106W103 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 21, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 21, 2021 |
Editas Medicine Announces Pricing of Offering of Common Stock Exhibit 99.1 Editas Medicine Announces Pricing of Offering of Common Stock CAMBRIDGE, Mass., Jan. 20, 2021 – Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering |
|
| January 21, 2021 |
Exhibit 1.1 Execution Version 3,500,000 Shares EDITAS MEDICINE, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT January 20, 2021 January 20, 2021 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As Representatives for the several Underwriters named in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1 |
|
| January 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 19, 2021 |
Exhibit 99.1 On December 14, 2020, the Patent Trial and Appeal Board of the USPTO (“PTAB”), declared a third interference between a pending U.S. patent application (U.S. Serial No. 14/685,510) that is owned by ToolGen and 14 U.S. patents (the 13 U.S. patents involved in one of two another existing interference involving our licensor The Broad Institute (“Broad”) and U.S. Patent No. 8,889,418) and |
|
| January 19, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 11, 2021 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to Rule 424(b)(7) Registration No. 333-223596 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, $0.0001 par value per share 303,599 $71.04 $21,567,672.96 $2,353.04 (1) Pursuant to Rule 41 |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 6, 2020 |
Termination Agreement, dated August 5, 2020, by and between the Registrant and Allergan Sales, LLC Exhibit 10.1 EXECUTION VERSION Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Agreement”) is entered into on August 5, 2020 (the “Effective Date”) by and between Editas |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2020 |
Exhibit 99.1 Editas Medicine Announces Third Quarter 2020 Results and Update EDIT-101 for LCA10 ‒ BRILLIANCE trial adult low-dose cohort completed EDIT-301 for sickle cell disease ‒ on track for IND filing by end of 2020 EDIT-201 for solid tumors ‒ preclinical data to be presented at SITC and ASH Cash, cash equivalents, and marketable securities of $541 million as of September 30, 2020 CAMBRIDGE, |
|
| October 9, 2020 |
EDIT / Editas Medicine, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 7, 2020 |
Separation Agreement, dated as of April 30, 2020, by and between the Company and Judith Abrams. Exhibit 10.2 11 Hurley Street Cambridge, MA 02141 P 617-401-9000 F 617-494-0985 VIA EMAIL April 30, 2020 Judith R. Abrams 102 Upper Mountain Avenue Montclair, NJ 07042 [email protected] Dear Judith: As we discussed, your employment with Editas Medicine, Inc. (the “Company”) will end effective May 1, 2020 (the “Separation Date”). As we also discussed, you will be eligible to receive the Benefi |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 7, 2020 |
Advisory Services Agreement, Dated May 1, 2020, by and between the Company and Judith Abrams Exhibit 10.3 EDITAS MEDICINE, INC. ADVISORY SERVICE AGREEMENT This Advisory Services Agreement (the “Agreement”), is signed concurrently with the Separation Agreement dated May 1, 2020, to which this Agreement is attached as Exhibit A (the “Separation Agreement”) and effective as of May 4, 2020 (the “Effective Date”) is entered into by Editas Medicine, Inc., a Delaware corporation (the “Company”), |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 6, 2020 |
Exhibit 99.1 Editas Medicine Announces Second Quarter 2020 Results and Update Regained full control of ocular medicines under new agreement with AbbVie BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020 Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Strengthened balance sheet through equity offering raising $216 million in gross proceeds Cas |
|
| June 25, 2020 |
Editas Medicine Announces Pricing of Offering of Common Stock Exhibit 99.2 Editas Medicine Announces Pricing of Offering of Common Stock CAMBRIDGE, Mass., June 23, 2020 – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000 shares of its common stock at a public offering price of $31.25 per share, before deducting underwriter discounts and commissions and estimated offeri |
|
| June 25, 2020 |
Editas Medicine Announces Offering of Common Stock Exhibit 99.1 Editas Medicine Announces Offering of Common Stock CAMBRIDGE, Mass., June 23, 2020 – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriter a 30-day option to purchase up to an additional 600,000 sh |
|
| June 25, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2020 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 25, 2020 |
Underwriting Agreement, dated June 23, 2020, by and between the Company and the Underwriter Exhibit 1.1 EXECUTION VERSION 6,000,000 Shares EDITAS MEDICINE, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT June 23, 2020 June 23, 2020 Morgan Stanley & Co. LLC As Representative for the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Editas Medicine, Inc., a Delaware corporation (th |
|
| June 25, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| June 23, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on June 23, 2020 Registration No. |
|
| June 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2020 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 15, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37687 46-4097528 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2020 |
Common Stock Sales Agreement, dated as of May 15, 2020, by and between the Company and Cowen Exhibit 1.1 Editas Medicine, Inc. $150,000,000 COMMON STOCK SALES AGREEMENT May 15, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1.Issuance and Sale of Shares. The Company agrees that, from time to t |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
